← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Alveolar Rhabdomyosarcoma

MONDO:0009994 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 33 citations openscientist · 45 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Alveolar rhabdomyosarcoma (fusion-positive RMS) is driven in roughly 80% of cases by a pathognomonic somatic chromosomal translocation fusing PAX3 or PAX7 to FOXO1, producing an aberrant fusion transcription factor.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Cooperative-group synthesis: ~80% of ARMS harbor PAX3/7::FOXO1 fusions.
Falcon reports the cooperative-group figure that ~80% of ARMS harbor PAX3/7::FOXO1 fusions as the central causal driver.
DOI:10.3390/cancers17193100
openscientist CONCORDANT 95% The PAX3-FOXO1 and PAX7-FOXO1 gene fusions occur in 80% of cases with the alveolar subtype and are more predictive of outcome than histologic classification
OpenScientist gives the same 80% fusion frequency and adds the precise translocations t(2;13) and t(1;13).
PMID:28058850

The PAX3/7-FOXO1 fusion protein is a constitutively active transcription factor that drives proliferative programs while blocking terminal myogenic differentiation.

MAJORITY INTEGRATED
pathophysiologygene_function
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% The resultant chimeric proteins are constitutively active transcription factors that drive oncogenesis by activating proliferative programs while simultaneously blocking terminal myogenic differentiation
OpenScientist states the dual mechanism (proliferation plus differentiation block) explicitly.
PMID:10534762
falcon PARTIAL 50% a PAX3/7::FOXO1 fusion forms an aberrant transcription factor in FP-RMS/ARMS.
Falcon frames the fusion as an aberrant transcription factor and the initiating genomic event, but does not spell out the proliferation-plus- differentiation-block duality; it emphasizes transcriptional reprogramming instead.

PAX3-FOXO1 exerts its oncogenic program largely through activation of (myogenic) super-enhancers and a core-regulatory transcription-factor network, creating a transcriptional/epigenetic addiction that is a therapeutic vulnerability.

UNANIMOUS INTEGRATED
pathophysiologygene_functiontreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% activates myogenic super-enhancers that define RMS cell identity including MYOD1, MYOGENIN and MYCN.
Falcon reports PAX3-FOXO1 pioneer-factor activation of myogenic super-enhancers and frames FP-RMS as transcriptionally/epigenetically addicted, motivating KDM3B-inhibitor targeting.
DOI:10.1038/s41467-023-43044-1, DOI:10.1038/s41467-024-45902-y
openscientist CONCORDANT 90% In alveolar rhabdomyosarcoma, PAX3-FOXO1 activates SEs to induce the expression of other CR TFs, providing a model system for studying cancer cell addiction to CR transcription
OpenScientist describes the same super-enhancer/core-regulatory addiction and the HDAC (entinostat) targeting rationale.
PMID:31285436, PMID:31113472

FOXO1 fusion status is the single most important prognostic biomarker in ARMS, and PAX3-FOXO1 confers worse outcomes than PAX7-FOXO1 or fusion-negative disease.

MAJORITY INTEGRATED
genetic_factorprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% Among nonmetastatic patients, patients who were PAX3/FOXO1 positive had a significantly poorer outcome compared with both alveolar-negative and PAX7/FOXO1-positive patients
OpenScientist asserts the PAX3-FOXO1-worse-than-PAX7-FOXO1 prognostic gradient with cohort data.
PMID:22454413
falcon PARTIAL 50% In RMS, PAX3–FOXO1 positivity correlated with lymph node metastasis, distant metastasis, and shorter overall survival, reinforcing fusion testing as clinically informative.
Falcon confirms that fusion positivity predicts worse outcome and clinical informativeness, but does not report the PAX3 vs PAX7 prognostic distinction.
DOI:10.3389/fcell.2023.1214262

ARMS is a rare, predominantly pediatric soft tissue sarcoma; RMS overall is an uncommon childhood cancer and the alveolar subtype makes up a minority of RMS cases.

UNANIMOUS INTEGRATED
epidemiologyphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 80% RMS accounts for ~3% of childhood cancers, with ~400–500 cases diagnosed annually in the United States (all RMS).
Falcon gives the childhood-cancer fraction and US annual case count for all RMS.
DOI:10.3389/fonc.2025.1570070
openscientist CONCORDANT 85% RMS overall: approximately 4.5 per 1,000,000 children per year; ARMS represents ~20–25% of these cases.
OpenScientist adds a per-million incidence for RMS and the ~20-25% alveolar-subtype fraction; framing differs but is complementary.

Standard-of-care for ARMS remains risk-stratified multimodal therapy — multi-agent chemotherapy (VAC/IVA backbone) combined with surgery and/or radiotherapy for local control.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% systemic multi-agent chemotherapy combined with surgery and/or radiotherapy for local control, delivered through risk-stratified cooperative-group protocols.
Falcon describes the multimodality, risk-stratified cooperative-group standard of care.
DOI:10.3390/cancers17193100
openscientist CONCORDANT 85% the best treatment to date still remains VAC combination therapy, first instituted as standard of care in the 1970s
OpenScientist names the VAC chemotherapy backbone as the enduring standard of care and details the surgery/radiation components.
PMID:41038289

Metastatic and relapsed ARMS/RMS carry an extremely poor prognosis, with high-risk/metastatic survival far below that of localized disease.

MAJORITY INTEGRATED
prognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% 5-year Overall and Event Free Survival were 32.0% (95% CI 29.2-34.9) and 27.5% (95% CI 24.8-30.2) respectively
OpenScientist quantifies the dismal metastatic (INSTRuCT M1) survival and the 8% post-relapse 3-year OS.
PMID:41721480, PMID:30351457
falcon PARTIAL 55% A broad RMS epidemiology review reports risk-group survival ranges (all RMS): low-risk ~70–90%, intermediate 50–70%, high-risk 20–30%, and highlights worse outcomes in fusion-positive disease.
Falcon gives broad risk-group survival ranges (high-risk 20-30%) and worse fusion-positive outcomes, but no metastatic- or relapse-specific figures.
DOI:10.22540/jrpms-09-046

The receptor tyrosine kinase / RAS / PIK3CA signaling axis is altered in ~93% of rhabdomyosarcomas, providing a framework for genomics-directed (e.g. FGFR4) therapy.

SINGLE LEAD
pathophysiologygenetic_factortreatment
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Alteration of the receptor tyrosine kinase/RAS/PIK3CA axis affects 93% of cases, providing a framework for genomics-directed therapies that might improve outcomes for patients with rhabdomyosarcoma
OpenScientist reports the 93% RTK/RAS/PIK3CA alteration and the FGFR4 transcriptional-target/therapy rationale.
PMID:24436047, PMID:42041178
falcon SILENT —
Falcon emphasizes the low overall mutational burden and epigenetic (KDM3B/super-enhancer) dependencies of FP-RMS and does not report the RTK/RAS/PIK3CA 93%-alteration axis.

The cell of origin of ARMS is unsettled: functional reprogramming studies show PAX3-FOXO1 can transform non-myogenic (endothelial) progenitors into fusion-positive RMS, challenging a strict skeletal-muscle-progenitor origin.

CONFLICT LEAD
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 85% PAX3-FOXO1 can reprogram endothelial progenitors into fusion-positive RMS, supporting a non-myogenic cell of origin and showing activation of myogenic super-enhancers.
Falcon foregrounds the non-myogenic (endothelial progenitor) cell-of-origin reprogramming model and notes ARMS can arise at sites devoid of skeletal muscle.
DOI:10.1038/s41467-023-43044-1
openscientist CONTRADICTORY 20% is an aggressive pediatric soft tissue sarcoma arising from skeletal muscle progenitor cells
OpenScientist asserts a skeletal-muscle-progenitor (myoblast/myogenic precursor) cell of origin, directly conflicting with Falcon's non-myogenic endothelial-reprogramming framing.

Narrative

Overview

Both providers frame alveolar rhabdomyosarcoma as an aggressive, predominantly pediatric soft tissue sarcoma defined molecularly by PAX3-FOXO1 / PAX7-FOXO1 fusion oncogenes, with the fusion transcription factor's super-enhancer-driven transcriptional program, fusion status as the dominant prognostic biomarker, multimodal chemotherapy/surgery/radiation care, and poor metastatic outcomes as the core curated concepts. Falcon is the more mechanism-/2023-2024- translational-focused report; OpenScientist is broader and more clinically quantitative.

Agreement

Both agree that ~80% of ARMS is fusion-positive (PAX3/7-FOXO1), that the fusion acts as an aberrant transcription factor activating super-enhancers / a core-regulatory network (an epigenetic addiction and therapeutic vulnerability), that fusion status is a key prognostic biomarker with worse outcomes in fusion-positive disease, that ARMS is a rare pediatric sarcoma, that standard care is risk-stratified multimodal chemotherapy plus local control, and that metastatic/high-risk disease has a poor prognosis.

Divergence

OpenScientist adds the near-universal RTK/RAS/PIK3CA axis alteration (93% of RMS) and its FGFR4-directed therapy framework, the precise PAX3-FOXO1-worse- than-PAX7-FOXO1 prognostic gradient, exact metastatic survival statistics (INSTRuCT 5-year OS 32%, post-relapse 3-year OS 8%), maintenance chemotherapy, CAR-T immunotherapy, and detailed site-specific prognosis and diagnostics. Falcon contributes the ctDNA prognostic biomarker, the single-cell RMS cell- state atlas, KDM3B-inhibitor epigenetic drug discovery, and — the one genuine conflict — a non-myogenic (endothelial progenitor) cell-of-origin model that contradicts OpenScientist's skeletal-muscle-progenitor origin. Quantitative framing differences on epidemiology and survival are complementary rather than contradictory.

Integration

Promote into kb/disorders/Alveolar_Rhabdomyosarcoma.yaml the fusion-driver biology (~80% PAX3/7-FOXO1), the constitutively active fusion transcription factor blocking myogenic differentiation while driving proliferation, the super-enhancer / core-regulatory transcriptional addiction as a therapeutic vulnerability, fusion status (PAX3-FOXO1 worse than PAX7-FOXO1) as the leading prognostic biomarker, pediatric epidemiology, multimodal standard of care, and the poor metastatic/relapse prognosis.

Not integrated (leads)

The RTK/RAS/PIK3CA 93%-axis / FGFR4-directed therapy framework and the non-myogenic cell-of-origin question are retained as research leads: the former is single-provider (OpenScientist only), and the latter is an unresolved provider conflict requiring primary-literature adjudication before a curated cell-of-origin claim is made. Investigational agents (HDAC/KDM inhibitors, CAR-T/CAR-NK, ctDNA monitoring) remain leads pending PMID/abstract verification.

Cross-provider synthesis comparing falcon (mechanism/translational-focused) and openscientist (comprehensive, clinically quantitative) deep-research reports for Alveolar Rhabdomyosarcoma. best_matching_text values are verbatim excerpts from the cited report files. The one genuine CONTRADICTORY stance is the cell-of-origin disagreement (non-myogenic endothelial reprogramming vs skeletal-muscle progenitor origin); all other divergences are coverage/framing differences, not conflicts. Literature evidence: blocks were intentionally left unpopulated pending fetch-reference verification of the underlying PMIDs/DOIs.